Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

Evotec SE

CIK 1412558Updated Nov 16, 2026

Name history
Evotec AG · through Sep 23, 2021

EVOTF price & chart

Provider market data

Loading TradingView…

OTC:EVOTF on TradingView ↗

TradingView · Data may be delayed

About the company

Evotec is a life science company pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, Evotec accelerates the journey from concept to cure with greater speed, intelligence and precision. The company's expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms including Molecular Patient Databases, PanOmics and induced pluripotent stem cell-based disease modeling. Through flexible partnering models tailored to customers' needs, Evotec works with all Top 20 pharmaceutical companies, more than 800 biotechnology companies, academic institutions and other healthcare stakeholders. Evotec's offerings range from standalone services to fully integrated research and development programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, the company is redefining biologics development and manufacturing to improve accessibility and affordability. With a portfolio of more than 100 proprietary research and development assets, most of which are co-owned, Evotec focuses…

6-K · 2026-11-05 · 0001104659-26-123049

Company description from the cited filing.

In the news

No coverage from other publishers is available.

Seeking Alpha

Recent filings

  1. 6-K filing

    6-K · 2026-11-05 · 0001104659-26-123049

  2. 6-K filing

    6-K · 2026-10-15 · 0001104659-26-116003

  3. 6-K filing

    6-K · 2026-10-14 · 0001104659-26-115678

  4. 6-K filing

    6-K · 2026-09-29 · 0001104659-26-111508

  5. 6-K filing

    6-K · 2026-09-09 · 0001104659-26-106064

Show 5 more recent filings
  1. 6-K filing

    6-K · 2026-08-13 · 0001104659-26-095267

  2. 6-K filing

    6-K · 2026-07-14 · 0001104659-26-083179

  3. 6-K filing

    6-K · 2026-06-30 · 0001104659-26-079222

  4. 6-K filing

    6-K · 2026-06-17 · 0001104659-26-074806

  5. 6-K filing

    6-K · 2026-05-06 · 0001104659-26-055957

Financials

FY 2024 · EUR
Revenue796,967,000EUR · FY 2024
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

Net income— · FY 2024
Assets—EUR · FY 2024
Cash— · FY 2024
Operating income-142,522,000EUR · FY 2024
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

Diluted EPS-1.11EUR/shares · FY 2024
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

Some figures are unavailable for this reporting year.

Balance-sheet figures are unavailable pending verification.

cash flow · annual statements
Line itemFY 2024FY 2023FY 2022FY 2021
Cash flows from operating activities:
Profit or LossEUR-196,078,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

-83,913,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

-175,655,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

215,510,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

Additional Financial Items
AdjustmentsForCurrentTaxOfPriorPeriodEUR-328,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

2,666,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

-156,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

4,095,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

AdjustmentsForDecreaseIncreaseInTradeAccountReceivableEUR——-38,429,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

-48,032,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociatesEUR-8,648,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

———
AdjustmentsForIncomeTaxExpenseEUR2,102,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

3,320,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

——
AdjustmentsForSharebasedPaymentsEUR5,035,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

9,630,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

9,919,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

7,805,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

GoodwillEUR282,854,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

As of 2024-12-31

275,635,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

As of 2023-12-31

274,819,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

As of 2022-12-31

257,569,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

As of 2021-12-31

IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesEUR-76,083,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

12,902,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

——
IncreaseDecreaseInWorkingCapitalEUR68,207,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

9,944,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

——
InterestPaidClassifiedAsFinancingActivitiesEUR5,920,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

12,853,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

——
InterestPaidClassifiedAsOperatingActivitiesEUR——9,798,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

5,429,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

InterestReceivedClassifiedAsOperatingActivitiesEUR——3,026,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

1,106,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR24,124,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

22,446,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

19,046,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

20,665,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

ProceedsFromBorrowingsClassifiedAsFinancingActivitiesEUR900,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

219,923,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

—30,791,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

ProceedsFromIssuingSharesEUR——355,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

403,126,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesEUR2,000,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

530,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

——
PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesEUR14,769,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

2,677,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

——
RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesEUR128,849,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

112,880,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

34,067,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

16,018,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemFY 2024FY 2023FY 2022FY 2021
Cost of Goods and Services Sold—
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

—
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

—
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

—
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

Selling, General and Administrative ExpenseEUR188,201,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

169,610,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

156,190,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

105,445,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

Total RevenueEUR796,967,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

781,426,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

751,448,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

618,034,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

Additional Financial Items
ApplicableTaxRatenumber0.32
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

0.32
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

0.32
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

0.32
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

AverageEffectiveTaxRatenumber-0.01
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

-0.04
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

-0.14
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

0.09
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

BasicEarningsLossPerShareEUR/shares-1.11
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

-0.47
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

-0.99
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

1.3
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

CurrentTaxExpenseIncomeEUR7,761,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

5,251,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

14,132,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

12,309,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

DeferredTaxExpenseIncomeRecognisedInProfitOrLossEUR-5,331,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

-4,597,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

7,722,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

5,066,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

DepreciationRightofuseAssetsEUR21,530,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

21,075,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

18,659,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

15,829,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

DilutedEarningsLossPerShareEUR/shares-1.11
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

-0.47
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

-0.99
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

1.3
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

EmployeeBenefitsExpenseEUR458,738,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

377,587,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

388,050,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

319,353,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsedEUR57,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

62,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

50,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

56,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedEUR283,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

236,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

476,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

839,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

GrossProfitEUR114,881,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

175,051,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

174,065,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

151,543,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

ImpairmentLossRecognisedInProfitOrLossGoodwillEUR0
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

0
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

0
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

0
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillEUR———683,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

IncomeTaxExpenseContinuingOperationsEUR2,102,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

3,320,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

21,698,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

21,470,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

InterestExpenseEUR——13,150,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

9,254,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

InterestExpenseOnLeaseLiabilitiesEUR4,727,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

5,831,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

3,841,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

3,728,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

OtherFinanceCostEUR11,699,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

11,739,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

—198,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

OtherIncomeEUR52,700,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

64,793,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

81,582,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

73,472,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

ProfitLossAttributableToOwnersOfParentEUR——-175,655,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

215,510,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

ProfitLossBeforeTaxEUR-193,977,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

-80,593,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

-153,957,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

236,980,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

ProfitLossFromOperatingActivitiesEUR-142,522,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

-47,507,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

20,850,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

40,996,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

ResearchAndDevelopmentExpenseEUR50,857,000
Source

20-F · 2025-04-17 · 0001104659-25-035638

2024-01-01 to 2024-12-31

68,529,000
Source

20-F · 2024-08-14 · 0001104659-24-089121

2023-01-01 to 2023-12-31

76,642,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

72,200,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

RevenueFromInterestEUR——8,336,000
Source

20-F · 2023-05-12 · 0001104659-23-059900

2022-01-01 to 2022-12-31

2,272,000
Source

20-F · 2022-04-26 · 0001104659-22-049929

2021-01-01 to 2021-12-31

Lines labelled “Derived” are calculated from reported figures.

Filing attachments

tm2629114d1_ex99-1.htm · 6-K · 2026-11-05

Exhibit 99.1 For further information, please contact: Dr. Sarah Fakih, EVP Head of Global Communications and Investor Relations, sarah.fakih@evotec.com, M. +49.(0)151 70 688 784, www.evotec.com INTERIM STATEMENT 9M 2026 HIGHLIGHTS 4 D&PD LEADING COMMERCIAL INDICATORS SHOW CONTINUED IMPROVEMENT 4 JUST – EVOTEC BIOLOGICS (“JEB”) Q3 PERFORMANCE AFFECTED BY PARTIAL MILESTONE ACHIEVEMENT; FULL-YEAR OUTLOOK IMPACTED BY MILESTONE TIMING, PROJECT SHI…

6-K · 2026-11-05 · 0001104659-26-123049

Read attachment ↗
tm2629114d1_ex99-2.htm · 6-K · 2026-11-05

Exhibit 99.2 Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals Financial performance: Q3 and nine-month Group revenue of €164.9 m and €465.0 m, respectively (Q3: €164.2 m, 9M: €477.4 m at CER); adj. Group EBITDA of -€1.6 m and -€44.3 m, respectively (Q3: -€1.7 m, 9M: -€39.1 m at CER) Robust commercial momentum: Net sales* in D&PD base business increased 24% vs. 9M 2025 accompanied by continued positive development across key comm…

6-K · 2026-11-05 · 0001104659-26-123049

Read attachment ↗
tm2627661d1_ex99-1.htm · 6-K · 2026-10-15

Exhibit 99.1 Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board Will lead Evotec’s global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovation Brings more than 25 years of global experience in pharma, biotechnology and academia Hamburg, Germany, October 15, 2026 - Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the appointmen…

6-K · 2026-10-15 · 0001104659-26-116003

Read attachment ↗
tm2627661d1_ex99-2.htm · 6-K · 2026-10-15

Exhibit 99.2 Notification of Major Holdings Page 1 | 3 Hamburg, Germany 22419 Manfred Eigen Campus / Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) X Acquisition/disposal of shares with voting rights Acquis…

6-K · 2026-10-15 · 0001104659-26-116003

Read attachment ↗
tm2627582d1_ex99-1.htm · 6-K · 2026-10-14

Exhibit 99.1 Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance Hamburg, Germany - Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for first nine months of 2026. Full financial results for the third quarter and the first nine months of 2026 will be published on Nov…

6-K · 2026-10-14 · 0001104659-26-115678

Read attachment ↗
tm2626558d1_ex99-1.htm · 6-K · 2026-09-29

Exhibit 99.1 Evotec Announces Chief Scientific Officer Transition Dr. Cord Dohrmann to step down as of September 30, 2026 ─────────────────────────────────────────────────────── Search ongoing for a successor Hamburg, Germany, September 29, 2026 - Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down effective September 30, 2026. The decision for Dr. Dohrmann to step down from his position was made…

6-K · 2026-09-29 · 0001104659-26-111508

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.